The company becomes profitable and peak sales per multiple analyst are around $3/$5B and at lets say mid teen royalty rate to Ionis.
it all depends on when you bought the stock
i bought my current core position at just below $4 on average in the early spring of 2005
i have sold shares as High as $72
I have no cost basis in the stock a very nice profit and holding just over $360K at the current price
Its not where a stock has been but where its going
your analysis should be done on MKT CAP not PPS from the IPO date that shows true value creation.
Best case is that they have some I's to dot and some T's to cross to get the P3 protocols excepted by the FDA Cardio division and will be starting P3 cardio/wild type TTR trial by September this year.
P3 for cardio TTR has not started in the U.S. it is in p3 in Japan.
GSK/IONIS are using the P1/P2 data from the Nuero TTR study to provide the data to support the protocols for the Cardio study. The cardio division of the FDA has some questions about the support package and if they can't get resolved than a P2 trial will have to be run with its own defined FDA agreed upon protocols.
So IONIS/GSK are looking at a 6 month to 24 month delay in Cadio/wild type TTR study.
you have been posting your skirtboy sit down to take a peea nonsense since like 2005
And the person who developed ALNY's GalNAc drug delivery program came from IONIS so it tell you whose shared (IONIS) IP was used for its core development.
He has bet on the wrong horse
antisense is a true platform, dsRNAi is not a real platform as each drug needs to be developed on an individual basis almost like small molecules and there is no predictability on their safety profile. ALNY is worth maybe $30 a share at best. Their TTRx infusion drug is going to be a flop and the SC version KD is about the same as IONIS version with a worst safety profile. ALNY has nothing in its pipeline worth talking about.